Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
A surveillance of respiratory tract related adverse events in patients treated with
Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies